Non-coding RNA in drug resistance of gastric cancer

Table 1 Summary of lncRNAs involved in multiple drug resistance in gastric cancer

Dysregulation	LncRNA	Pathway/target	Corresponding drugs	Ref.
Up-regulated	PVT1	MDR1, MRP1, mTOR, HIF-1a	DDP	[22]
Up-regulated	AK022798	MRP1, Caspase 3/8, P-gp, Notch1	DDP	[23]
Up-regulated	HOTAIR	PI3K/AKT/MRP1, Wnt/β-catenin, miR-34a	DDP	[24,25]
Up-regulated	MRUL	ABCB1, P-gp, PRL23, RPS13, JNK1, CPP32	DOX, ADR	[26]
Up-regulated	ANRIL	MDR1, MRP1	DDP, 5-Fu	[27]
Up-regulated	UCA1	miR-27b, Bcl-2, Cleaved caspase-3	DDP, 5-Fu, ADR	[28]
Up-regulated	MALAT1	miR-23b-3p, ATG3/12, Autophagy	5-Fu, VCR, DDP	[29]
Up-regulated	GHET1	MDR1, MRP1, Bax, Bcl-2	DDP	[30]
Up-regulated	CASC9	MDR1	PTX, ADR	[31]
Up-regulated	ZFAS1	Wnt/β-catenin, NKD2	PTX, DDP	[32]
Up-regulated	HULC	Induced EMT, Suppressed apoptosis	DDP, ADR, 5-Fu	[33,34]
Up-regulated	BLACAT1	ABCB1, MDR1, MRP1, LRP1, miR-361	OXA	[35]

DDP: Cisplatin; 5-Fu: 5-fluorouracil; VCR: Vincristine; ADR: Adriamycin; PTX: Paclitaxel; DOX: Doxorubicin; OXA: Oxaliplatin.